Romiplostim injection for treatment-resistant ITP
Treatments studied
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This trial tests romiplostim, a weekly injection, for patients with ITP (a blood disorder where the body destroys its own platelets) who did not respond to or could not tolerate oral medications. It aims to help raise platelet counts and reduce bleeding risk.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18 or older with diagnosed primary ITP (immune system attacking your own platelets)
- Failed previous oral platelet-boosting drugs (eltrombopag, hetrombopag, or avatrombopag) due to poor response, loss of response, or side effects
- Platelet count below 30×10⁹/L confirmed by at least two blood tests at least 5 days apart
- Able to receive weekly injections under the skin and follow all study visits and procedures
- No previous romiplostim treatment, recent spleen removal, or blood clots; no severe liver, kidney, or heart disease
- For women: negative pregnancy test and agreement to use birth control during the study and 3 months after
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two medicines—romiplostim N01 (a shot to raise platelets) and rituximab (an infusion that calms the immune system)—for people with primary immune thrombocytopenia (ITP) who have not had enough improvement from oral TPO-RA pills like hetrombopag or eltrombopag. It aims to see if this combination works better and is safe.
This trial compares two drugs, romiplostim and rhTPO, to help increase platelet counts after a stem cell transplant in people with MDS or aplastic anemia. The goal is to see which drug works better at reducing the need for platelet transfusions.
This trial tests whether a weekly injection of romiplostim can safely raise platelet counts in children with chronic immune thrombocytopenia (ITP) that has not improved with standard treatments. If effective, it may reduce bleeding risk and help children avoid more severe complications.
This trial tests a combination of romiplostim (a platelet-boosting drug) and steroids as the first treatment for adults with newly diagnosed immune thrombocytopenia (ITP). It aims to see if this approach can safely and effectively raise platelet counts.
This trial tests if adding romiplostim (a drug that helps make platelets) to standard steroid treatment works better than steroids alone for adults who have not been treated for ITP before. It is for people with low platelet counts and may help reduce bleeding.
This trial compares two ways to raise platelet counts in people with immune thrombocytopenia (ITP) who did not get enough benefit from a short course of a standard medicine. One option is a higher dose of a similar medicine, and the other is switching to a different pill. The goal is to find a treatment that works better with fewer side effects.
Hear when a new Immune (Idiopathic) Thrombocytopenic Purpura (ITP) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.